Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended		107 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014
Income Statement [Abstract]
REVENUES	$ 0	$ 0	$ 0	$ 0	$ 0
COST AND EXPENSES
Research and Development	0	3,000	13,867	9,509	1,296,262
General and Administrative	132,975	196,444	459,411	1,170,092	8,676,352
Depreciation and Amortization					2,668
Consulting and Professional Fees	39,995	51,703	147,998	123,022	5,372,419
Impairment of Goodwill and Intangibles					34,688
Total Costs and Expenses	172,970	251,147	621,276	1,302,623	15,382,389
OPERATING LOSS	(172,970)	(251,147)	(621,276)	(1,302,623)	(15,382,389)
OTHER INCOME & (EXPENSES)
Interest Expense	(8,981)	(12,321)	(26,388)	(32,239)	(486,554)
Loss on Early Extinguishment of Debt	0	0	0	0	(41,688)
Loss on Settlement of Debt through Equity Issuance	0	0	(984,730)	0	(984,730)
Interest Expense attributable to amortization of discount	0	(15,321)	0	(446,858)	(829,709)
Interest Income	14	0	14	0	320
Securities issued pursuant to contractual obligations	0	0	0	(35,223)	(101,595)
Other Income	490	0	490	0	237,406
Gain on de-consolidation of subsidiary	0	0	0	0	41,645,688
Loss on sale of Available for Sale Securities	0	0	0	0	(487,900)
Loss on disposal of Equipment	0	0	0	0	(531,571)
Other Expense	(65,000)	0	(65,000)	0	(65,166)
Total Other Income & (Expense)	(73,477)	(27,642)	(1,075,614)	(514,320)	38,354,501
NET INCOME (LOSS) before loss attributable to noncontrolling interest in Entest Biomedical, Inc. and equity in subsidiary losses	(246,447)	(278,789)	(1,696,890)	(1,816,943)	22,972,112
(Net Income) Loss attributable to noncontrolling interest in Entest Biomedical, Inc.	0	0	0	0	536,961
NET INCOME (LOSS) before equity in subsidiary losses	(24,644)	(278,789)	(1,696,890)	(1,816,943)	23,509,073
Equity in Net Income (Loss) of Entest	0	0	0	0	(663,649)
NET INCOME (LOSS)	(246,447)	(278,789)	(1,696,890)	(1,816,943)	22,845,424
Less: (Net Income)Loss attributable to noncontrolling interest Regen Biopharma, Inc.	66,388	0	144,927	0	153,760
NET INCOME (LOSS) available to common shareholders	$ (180,059)	$ (278,789)	$ (1,551,963)	$ (1,816,943)	$ 22,999,184
BASIC AND FULLY DILUTED EARNINGS (LOSS)	$ (0.0001)	$ (0.0002)	$ (0.0006)	$ (0.0016)
Weighted average number of shares outstanding	2,951,045,145	1,776,048,314	2,819,220,513	1,154,891,111